DBV Technologies (DBVT) Net Margin (2020 - 2026)
DBV Technologies (DBVT) posted Net Margin of 7200.0% for Q2 2026, down 36.13% sequentially from 5288.89% in Q1 2026, and down 440667.0% YoY from N/an in Q2 2025.
Powered by 
Analysis
DBV Technologies (DBVT) Net Margin (2020 - 2026) Analysis & Trends
DBV Technologies has reported Net Margin for 7 years, with the latest figure at 7200.0% in Q2 2026.
- Quarterly Net Margin fell 440667.0% year-over-year to 7200.0% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 3506.54% (down 39217.0% YoY) and the FY2025 annual result came in at 2607.29%, up 10504.0% from the prior year.
- Net Margin declined to 7200.0% in Q2 2026 per DBVT's latest filing, from 5288.89% in the prior quarter.
- Over five years, Net Margin peaked at 3009.28% in Q4 2022 and troughed at 7200.0% in Q2 2026.
- A 5-year average of 2298.69% and a median of 1725.15% in 2022 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2026: Net Margin jumped 347558 bps in 2022, then slumped 440667 bps in 2026.
- Over 5 years, Net Margin stood at 3009.28% in 2022, then slumped by 104 bps to 126.04% in 2023, then slumped by 3161 bps to 4109.82% in 2024, then slumped by 69 bps to 6950.23% in 2025, then dropped by 4 bps to 7200.0% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 7200.0%, 5288.89%, and 6950.23% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | DBV Technologies | 5.88 Bn | 5.70 Bn | - | -7,200.00% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7,200.00% |
| Mar 31, 2026 | -5,288.89% |
| Dec 31, 2025 | -6,950.23% |
| Sep 30, 2025 | -1,195.53% |
| Jun 30, 2025 | -2,793.33% |
| Mar 31, 2025 | -3,387.50% |
| Dec 31, 2024 | -4,109.82% |
| Sep 30, 2024 | -2,839.74% |
| Jun 30, 2024 | -2,852.37% |
| Mar 31, 2024 | -1,943.50% |
| Dec 31, 2023 | -126.04% |
| Sep 30, 2023 | -705.56% |
| Jun 30, 2023 | -1,059.57% |
| Mar 31, 2023 | -937.15% |
| Dec 31, 2022 | 3,009.28% |
| Sep 30, 2022 | -833.51% |
| Jun 30, 2022 | -1,506.80% |
| Mar 31, 2022 | -656.17% |
| Dec 31, 2021 | -466.30% |
| Sep 30, 2021 | -1,816.55% |